Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Neuilly-Sur-Seine – page 131

3 430 clinical trials in Neuilly-Sur-Seine, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Neuilly-Sur-Seine at a glance
3 430
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

3 430 trials in Neuilly-Sur-Seine

Open in trial search

Conjunctivitis allergic+1

Not yet recruiting

A Study Comparing Tacrolimus and Ciclosporin Eye Drops for Children and Adults with Moderate to Severe Vernal Keratoconjunctivitis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Ciclosporin
  • Sponsor:Laboratoires Thea

A Study of Bevacizumab for Adults with Long-Lasting Breathing Problems After COVID-19 Infection

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Acquired ATTR amyloidosis

Not yet recruiting

A Study of Acoramidis for Long-Term Safety in Patients with Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acoramidis Hydrochloride
  • Sponsor:Eidos Therapeutics Inc.

Appendicitis

Not yet recruiting

Study comparing amoxicillin/clavulanic acid treatment versus surgery for children with uncomplicated appendicitis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Amoxicillin
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Deafness

Not yet recruiting

Study of Aspirin and Folic Acid Treatment for Patients with Sudden Sensorineural Hearing Loss

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Assistance Publique Hopitaux De Paris

Non-small cell lung cancer

Not yet recruiting

Study of zipalertinib plus chemotherapy versus placebo plus chemotherapy in patients with stage IB-IIIA non-small cell lung cancer with uncommon EGFR mutations after surgery

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Taiho Oncology Inc.

Hepatocellular carcinoma

Not yet recruiting

Study of durvalumab and tremelimumab with or without hepatic arterial infusion of gemcitabine and oxaliplatin in patients with high tumor burden hepatocellular carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Unicancer

Erysipelas

Not yet recruiting

Comparison of compression therapy alone versus compression therapy with phenoxymethylpenicillin for preventing recurrent erysipelas in lower limbs

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Phenoxymethylpenicillin
  • Sponsor:Centre Hospitalier Regional Universitaire De Tours

Cardiac arrest

Not yet recruiting

Study comparing low-dose versus standard-dose epinephrine for better brain recovery in patients with out-of-hospital cardiac arrest

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Epinephrine Bitartrate
  • Sponsor:CHRU De Nancy

Transitional cell carcinoma

Not yet recruiting

Study of disitamab vedotin alone or with pembrolizumab in patients with locally advanced or metastatic urothelial cancer that expresses HER2

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Disitamab Vedotin
  • Sponsor:Seagen Inc.

Breast cancer metastatic

Not yet recruiting

Study of tucatinib and trastuzumab for patients with HER3-mutant and HER2-not amplified metastatic breast cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab
  • Sponsor:Institut Curie

Systemic lupus erythematosus+1

Not yet recruiting

Study of CC-97540 CD19-targeted CAR T cells in patients with systemic lupus erythematosus who did not respond to previous immunosuppressive treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:CC-97540
  • Sponsor:Celgene Corp.

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Neuilly-Sur-Seine

What the registry says about research in the country

01 Gastrointestinal Research

Extensive clinical trials focusing on inflammatory bowel diseases, particularly investigating innovative treatments for Crohn's Disease and Ulcerative Colitis. Multiple studies are evaluating novel therapeutic approaches for patients with moderate to severe conditions.

  • Crohn's Disease Management
  • Ulcerative Colitis Treatments
  • Post-operative Care Studies

Research includes both induction and maintenance therapies, with emphasis on long-term patient outcomes.

02 Cardiovascular Studies

Innovative research in cardiac conditions, including studies on acute myocarditis treatment and prevention of post-operative complications. Trials are examining both therapeutic and preventive approaches.

  • Myocarditis Treatment
  • Post-operative Care
  • Cardiac Surgery Outcomes

Focus on improving patient outcomes through targeted interventions and innovative surgical techniques.

03 Oncology Research

Advanced studies in cancer treatment, including trials for head and neck squamous cell carcinoma and colorectal cancer. Research focuses on both targeted therapies and combination treatments.

  • Metastatic Cancer Treatment
  • Colorectal Cancer Management
  • Prostate Cancer Therapy

Emphasis on developing personalized treatment approaches and improving survival rates.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.